Industry

DUBLIN–(BUSINESS WIRE)–The “End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States End Stage Renal Disease Market size was estimated at USD 7,173.99 million in 2021, USD 8,638.02 million … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Caspofungin Market Research Report 2022 (Status and Outlook)” report has been added to ResearchAndMarkets.com’s offering. The Global Caspofungin Market Size was estimated at USD 414.36 million in 2021 and is projected to reach USD 539.35 million by 2028, exhibiting a CAGR of 3.84% during the forecast period. The report provides a deep … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Allergic Rhinoconjunctivitis – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. The report provides current treatment practices, emerging drugs, Allergic Rhinoconjunctivitis market share of the individual therapies, current and forecasted Allergic Rhinoconjunctivitis market Size from 2019 to 2032 segmented by seven major markets. The report also covers … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Extracorporeal Shock Wave Therapy Devices Market Insights, Competitive Landscape and Market Forecast-2025” report has been added to ResearchAndMarkets.com’s offering. The report delivers an in-depth understanding of Extracorporeal Shock Wave Therapy Devices and the historical and forecasted Extracorporeal Shock Wave Therapy Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW. … [Read more…]

LONDON–(BUSINESS WIRE)–Element Materials Technology (Element), a global leader in testing, inspection, and certification (TIC) services, has completed its acquisition by Temasek, a global investor headquartered in Singapore. Temasek has been a minority shareholder in Element since 2019. Temasek has acquired Element from Bridgepoint, whose successful ownership has been an important part of a more than … [Read more…]

Positive biomarker data confirmed in additional subjects and at additional timepoints Stable or continuously increasing cognitive, language and motor functions observed in patients treated at ≤31 months of age, including subjects with SGSH mutations associated with the severe disease phenotype Full data analysis in Q3 2022 before discussions with regulatory authorities on next steps PARIS–(BUSINESS … [Read more…]

The oversubscribed first close of Series B funding was led by Cathay Health, joined by Credit Mutuel Innovation, Kurma Partners and BNP Paribas Développement. Funds will accelerate the execution of the Company’s product development towards a new standard of care for knee replacement interventions. PARIS–(BUSINESS WIRE)–#biotech—Ganymed Robotics, a developer of computer vision software and robotics … [Read more…]

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion’s management in three scientific conferences in July 2022. Laurent Desire, Ph.D., Sensorion’s … [Read more…]

Elevate Care calls on area healthcare partners to make $5,000 matching donations SKOKIE, Ill.–(BUSINESS WIRE)–#HealthcarePartnersforHighlandPark–Healthcare operators and partners across Chicagoland are coming together to help Aiden McCarthy, a 2-year-old boy who lost both of his parents in the Highland Park 4th of July parade shooting. Using #HealthcarePartnersforHighlandPark, Elevate Care started this movement feeling the desire … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma (MM) and … [Read more…]